Start your FREE trial now ADVERTISEMENT heading description username ADVERTISEMENT
Delayed generic entry translates directly into higher drug prices for payers, employers, and patients
Understanding GLP-1 related fatigue helps set realistic expectations during the adjustment period
RESULTS A total of 22 691 922 patients 45 years of age with overweight or obesity and ASCVD were identified with 14 483 receiving semaglutide and 10 642 receiving tirzepatide and fulfilling the remaining inclusion criteria (Figure 1)
Thats because exendin-4 was close enough in its amino-acid sequence to provide the same effects as GLP-1, yet different enough that the same enzymes that broke down GLP-1 so quickly didnt have the same effect
He has also served on the speakers bureau of AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Menarini/Berlin Chemie, Merck, Sharp & Dohme, Novo Nordisk, and Sun Pharma